Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 50mg | $29.99 | $0.60/mg | In stock | Jul 14 |
| vial | 250mg | $94.99 | $0.38/mg | In stock | Jul 14 |
| vial | 500mg | $164.99 | $0.33/mg | In stock | Jul 14 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| GK50-260318 | Mar 2026 | 99.9% | Freedom Diagnostics | — | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does IDUN Peptides sell GHK-Cu?
Yes — IDUN Peptides currently lists GHK-Cu in 3 variants starting at $164.99 ($0.33/mg).
Is IDUN Peptides's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for IDUN Peptides's GHK-Cu, with the most recent showing 99.9% purity. IDUN Peptides holds an overall trust grade of C (73/100) across all 21 COAs on file.
What is IDUN Peptides's trust grade for GHK-Cu?
IDUN Peptides has an overall Disclosed Labs trust grade of C (73/100), computed from 21 COAs across all peptides. The most recent GHK-Cu COA was issued by Freedom Diagnostics.
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with IDUN Peptides's listing at $0.33/mg. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs